How much weight loss do people typically see when starting Ozempic (semaglutide) on top of insulin?
Ozempic (semaglutide) used with insulin can lead to weight loss, but the exact amount varies by dose, study design, and patients’ baseline weight and insulin regimen. In clinical trial populations where semaglutide was added to existing insulin therapy, weight reductions were generally in the range of about 4% to 6% from baseline over roughly 30–60 weeks, rather than the double-digit weight losses sometimes seen in broader obesity-focused populations.
What do clinical trials show when Ozempic is added to existing insulin?
Across trials that evaluated semaglutide in people already using insulin, mean weight change tended to be modest-to-moderate (single-digit percentage decreases). These studies typically also tracked changes in insulin dose and glucose control, which can affect appetite and weight outcomes.
What affects how much weight loss you might get?
Weight change can differ because of:
- Dose: higher semaglutide doses often produce more weight loss than lower doses.
- Starting insulin regimen: more insulin or higher doses can raise calorie intake and promote weight gain before GLP-1 treatment helps counter it.
- Baseline body weight and diabetes severity.
- How quickly the semaglutide dose is increased and how well it is tolerated (dose-limiting side effects can slow titration).
How should patients think about “typical” expectations?
A “typical” range for people adding Ozempic to insulin is usually single-digit percentage weight loss over about a year. Some people lose less, and some lose more, but the most consistent pattern in insulin-add-on studies is moderate weight reduction rather than dramatic loss.
When could weight change be smaller or not happen?
Weight loss may be smaller if:
- The insulin dose is not reduced despite improved glucose control.
- Side effects limit consistent dosing.
- Appetite suppression is limited.
- Baseline weight is lower (less absolute loss possible).
What about risks like hypoglycemia and insulin dose adjustments?
Adding Ozempic to insulin can raise hypoglycemia risk unless insulin doses are adjusted. Clinicians often reduce insulin when starting or escalating semaglutide to lower this risk, which can also influence weight outcomes.
---
Sources
I don’t have access to the specific Ozempic + insulin trial datasets or label text in the information provided here, so I can’t cite the exact percentage figures responsibly. If you share the study name(s) or the Ozempic label excerpt you’re using (or your country/label version), I can give a precise “typical” weight-loss range with exact citations.